HR+/HER2- ADVANCED BREAST CANCER

This study tests a new oral drug called AVZO-023, which blocks a protein (CDK4) that helps cancer cells grow. It is being tested alone or with other drugs in 380 adults with advanced solid tumors, especially a type of breast cancer called HR+/HER2-. The goal is to find a safe dos…

This study tests whether an artificial intelligence model can identify patients with advanced HR+ HER2- breast cancer whose tumors might still respond to a second CDK4/6 inhibitor after the first stopped working. About 105 participants will either receive the AI-recommended drug …

This early-phase study tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors o…

This study is testing a drug called dalpiciclib in people with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the drug can keep the cancer from growing and what side effects it causes. About 103 participants will take dalpicicl…

This study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…

This study tests a new drug combination (invikafusp alfa plus sacituzumab govitecan) in people with advanced breast cancers that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and can shrink or control tumors. About 50 adults with tripl…

This early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants…

This program provides access to the drug alpelisib for adults with advanced hormone-positive, HER2-negative breast cancer that has a specific genetic mutation (PIK3CA) and has progressed after standard hormone therapy. It's designed for patients who meet specific health criteria …

This real-world study follows 245 people with HR+/HER2- advanced breast cancer who are taking CDK4/6 inhibitors combined with hormone therapy. Researchers want to see how long the treatment controls the cancer and what options work best after the cancer becomes resistant. The goa…